Iúil 2022: De réir an taighde is déanaí a rinne Emergen Research, shroich an margadh domhanda le haghaidh teiripe T-chealla CAR méid $ 1.29 billiún in 2021 agus táthar ag súil go gcláróidh sé CAGR ioncaim de 24.9 faoin gcéad thar thréimhse na tréimhse réamhaisnéise. Táthar ag súil go mbeidh an méadú ar mhinicíocht ailse ar fud an domhain chomh maith leis an ráta mortlaíochta méadaitheach de bharr ailse mar phríomhthiománaithe an fháis ioncaim sa mhargadh domhanda teiripe cille CAR-T thar thréimhse na tréimhse réamhaisnéise. Is fachtóirí iad go léir a chuireann le fás an ioncaim sa mhargadh domhanda teiripe T-chealla CAR iad leathnú gníomhaíochtaí trialach cliniciúla ag luas mear, iomadú cumaisc agus éadálacha, agus mealltacht na dtairiscintí poiblí tosaigh.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Teiripe T-Cill CAR market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Teiripe T-Cill CAR market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Léiríonn torthaí suntasacha breise ón tuarascáil sin
In 2021, the segment of diffuse large B-cell liomfóma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with Teiripe T-chealla receptor antigen chimeric, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell limfomas neamh-Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Déantar tuilleadh imscrúduithe sa tuarascáil seo ar na príomhchuideachtaí atá ag feidhmiú sa mhargadh faoi láthair, mar atá a bpróifílí cuideachta, punanna táirgí, straitéisí leathnaithe, agus comhghuaillíochtaí straitéiseacha. I measc roinnt samplaí de na comhghuaillíochtaí seo tá cumaisc agus éadálacha, comhoibrithe, agus comhfhiontair. Ina theannta sin, tugann sé buaicphointí faoi éachtaí agus seasaimh airgeadais na cuideachta, chomh maith le léargais ar shroicheadh margaidh agus ar sheasamh domhanda na cuideachta.
Cuideachtaí a bhfuil próifíl acu sa mhargadh domhanda CAR T-Cell Therapy:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., agus Eli Lilly and Company .
Léigh tuilleadh ar thuarascáil mhargaidh domhanda CAR T-Cell Therapy ag: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
